Aluminum hydroxide
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | GAVISCON | — | 1983-12-09 | fda.gov ↗ |
Trials 29
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 67 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aluminum hydroxide | “The toxoids, either alone or in combination with aluminum hydroxide (Al(OH)3), were administered to healthy adults 50-85 years of age at antigen dose levels of 50, 100, or 200...” PMID 26993331 ↗ Mar 201634“Aluminum hydroxide suspension 2% is a pyrogen free, sterilized aluminum hydroxide wet gel suspension, placed into 2 mL Type 1 vials, containing an aluminum concentration of 10 mg/mL.” NCT05983874 ↗ “We assessed an Alhydrogel (aluminum hydroxide)-adjuvanted vaccine formulation at three ICC-1132 dose levels, each injected intramuscularly (1.0 mL) on study days 0, 56 and 168.” PMID 18253503 ↗ Feb 2008 “Investigational vaccine composed of Trimer 4571 100mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent” NCT04985760 ↗ “Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent” NCT02382640 ↗ “Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection” NCT02153112 ↗ “Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg.” NCT06321796 ↗ “Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg.” NCT06503978 ↗ “30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)” NCT01281501 ↗ “admixed with Aluminum Hydroxide Suspension (~625 mcg aluminum content)” NCT03284710 ↗ “200 mg aluminum hydroxide/200 magnesium hydroxide/25 mg simethicone” NCT05109390 ↗ |
| Known as | Al(OH)(3) | “The toxoids, either alone or in combination with aluminum hydroxide (Al(OH)3), were administered to healthy adults 50-85 years of age at antigen dose levels of 50, 100, or 200...” PMID 26993331 ↗ Mar 20161“with or without aluminum hydroxide adjuvant [Al(OH)(3)]” PMID 19773098 ↗ Mar 2009 |
| Known as | Alhydrogel | “Aluminum hydroxide adjuvant (Alhydrogel®);given with SARS vaccine; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine with adjuvant at 5 micrograms per...” NCT01376765 ↗25“Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b,...” PMID 28947345 ↗ Sep 2017 “intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)” NCT01949909 ↗ “A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®” NCT02236052 ↗ |
| Known as | AlOH | “We evaluated the dose-sparing potential of aluminum hydroxide (AlOH) adjuvant.” PMID 18808338 ↗ Nov 2008 |
| Known as | alum | “Investigational vaccine composed of Trimer 4571 100mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent” NCT04985760 ↗2“Aluminum hydroxide suspension (Alum) to be administered as 250 mcg (aluminum content) admixed with 426c.Mod.Core-C4b with 3M-052-AF.” NCT06613789 ↗ “aluminum hydroxide (alum)” NCT00001042 ↗ |
| Known as | aluminum hydroxide adjuvant (alum) | “Alhydrogel®, aluminum hydroxide adjuvant (alum)” NCT02067676 ↗ |
| Known as | aluminum hydroxide gel | “V180 adjuvanted with Alhydrogel™ (aluminum hydroxide gel, Brenntag Biosector, Frederikssund, Denmark) (N = 8), or placebo (N = 4)” PMID 32394880 ↗ May 2020 |
| Known as | aluminum hydroxide suspension | “Alhydrogel® (aluminum hydroxide suspension)” NCT00705835 ↗ |
| Known as | MSP3-CRM-Vac4All/ Alhydrogel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05197751 ↗ |
| Known as | Pfs25-EPA/Alhydrogel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01867463 ↗ |
| Known as | Pfs25H-EPA/Alhydrogel | “Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum” PMID 30061051 ↗ Jul 2018 |
| Modality | Other / unclassified | “The vaccine is mixed with Alhydrogel® (Registered Trademark), a material that is commonly added to vaccines to make them work better (also called an adjuvant).” NCT00427167 ↗ |
| Route | Intramuscular | “with or without aluminum hydroxide adjuvant by intramuscular (IM) injection” NCT00296634 ↗ |